

brentuximab vedotin powder for concentrate for solution for infusion (Adcetris®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2762	for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/08/2025	22/10/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9372/brentuximab-vedotin-adcetris-final-july-2025-for-website.pdf				

dupilumab 300 mg solution for injection in pre-filled pen or pre-filled syringe (Dupixent®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2801	in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.	Not routinely available as not recommended for use in NHS Scotland	11/08/2025	23/07/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9373/dupilumab-dupixent-final-july-2025-for-website.pdf				

zanubrutinib hard-capsules (Brukinsa®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2819	as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	Available in line with local or regional guidance	11/08/2025	18/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9371/zanubrutinib-brukinsa-abb-final-july-2025-for-website.pdf				
ripretinib tablets (Qinlock®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2821	for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Routinely available from a specialist centre in another health board	11/08/2025	18/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9369/ripretinib-qinlock-resub-final-july-2025-for-website.pdf				

mirikizumab solution for injection in pre-filled pen and concentrate for solution for infusion (OmvoH®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2822	for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	11/08/2025	30/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9368/mirikizumab-omvoh-abb-final-july-2025-for-website.pdf				
letermovir film-coated tablets and concentrate for solution for infusion (Prevymis®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2853	for prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].	Not routinely available as not recommended for use in NHS Scotland	11/08/2025	23/07/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9367/letermovir-prevymis-non-sub-final-july-2025-for-website.pdf				

trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2854	for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.	Not routinely available as not recommended for use in NHS Scotland	11/08/2025	23/07/2025
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9370/trastuzumab-deruxtecan-enhertu-non-sub-final-july-2025-for-website.pdf				